Ecdysterone vs LGD-4033
Moderate Research vs Moderate Research
avoid Mechanism-based · 64% Both Ecdysterone and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Ecdysterone LGD-4033
Weight 480.64 Da 338.25 Da
Half-life ~4-9 hours ~24-36 hours
Type Ecdysteroid (C27H44O7) Nonsteroidal selective androgen receptor modulator (C14H12F6N2O)
Key Benefits
Ecdysterone
01 Activation of muscle protein synthesis through ERbeta/PI3K/Akt/mTOR signaling without androgen receptor binding
02 Statistically significant increases in lean muscle mass demonstrated in a controlled human trial in trained subjects
03 No hormonal suppression -- does not affect testosterone, LH, or FSH levels, eliminating the need for post-cycle therapy
04 No androgenic side effects (no hair loss, acne, prostate issues, or virilization in women)
05 No hepatotoxicity, unlike oral anabolic steroids that undergo 17-alpha alkylation
06 Naturally occurring in common foods (spinach, quinoa), with a long history of safe dietary exposure
07 Compatible with other performance compounds due to its non-hormonal mechanism
08 Available as a dietary supplement without prescription in most jurisdictions
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Dosing Protocols
Ecdysterone
500-1000 mg/day (oral) or 50-100 mg/day (injectable) / 1-2x daily
Enhanced Anabolic Effect / Higher Bioavailability 50-100 mg/day Once daily
LGD-4033
5-10 mg/day / Once daily (oral)
Side Effects
Ecdysterone
Mild gastrointestinal discomfort (nausea, bloating, or stomach upset) with oral doses, particularly at higher dosages taken without food
Injection site pain, redness, or mild swelling with injectable administration
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Contraindications
Known allergy to ecdysteroids or spinach-derived compounds
Pregnancy and breastfeeding (insufficient safety data)
Individuals with estrogen-sensitive conditions should consult a physician, though ERbeta activation is generally considered protective rather than proliferative
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Research Evidence
Ecdysterone LGD-4033
Status Moderate Research Moderate Research
References 5 studies 5 studies
Latest 2020 2018
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.